11
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Multi-facetted impulsivity following nigral degeneration and dopamine replacement therapy

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Impulse control disorders (ICDs) are debilitating side effects of dopamine replacement therapy (DRT) in Parkinson’s disease (PD) that severely affect the quality of life of patients. While DRT, the pattern and extent of neurodegeneration, and prodromic factors of vulnerability (e.g. impulsivity) have all been hypothesized to play a role in the development of ICDs, their respective, and potentially interacting, contributions remain to be established. High impulsive (HI), Intermediate (Int) or low impulsive (LI) rats were identified based on their performance in both a differential reinforcement of low rate of responding (DRL) and a fixed consecutive number (FCN) schedules, that operationalize two independent facets of impulsivity, waiting and action inhibition (motor impulsivity). We investigated whether high impulsivity trait influenced the progressive development of a parkinsonian state induced by viral-mediated overexpression of α-synuclein, and whether impulsivity trait and nigrostriatal neurodegeneration independently or jointly influenced the effects of DRT on impulse control. α-synuclein-induced nigrostriatal neurodegeneration increased both waiting and motor impulsivity. The D2/D3 dopamine receptor agonist pramipexole exacerbated motor impulsivity more than waiting. However, the pramipexole-induced increase in waiting impulsivity observed in both sham and lesioned rats, was more pronounced in HI lesioned rats, which displayed a restricted α-synuclein-induced dopaminergic neurodegeneration. Thus, a PD-like nigrostriatal lesion increases both motor and waiting impulsivity, but its interaction with a pre-existing impulsivity trait, which, at the cellular level, confers resilience to dopaminergic neurodegeneration, worsens the detrimental effects of D2/D3 dopamine receptor agonists on inhibitory control.

          Highlights

          • Degeneration of the substantia nigra increases both waiting and action impulsivity.

          • Reduced alpha-synuclein-induced degeneration in high impulsive rats.

          • Pramipexole increases waiting and action impulsivity in sham and lesioned rats.

          • Exacerbated effect of pramipexole in high impulsive vs. low impulsive lesioned rats.

          Related collections

          Most cited references40

          • Record: found
          • Abstract: found
          • Article: not found

          Dopaminergic network differences in human impulsivity.

          Dopamine (DA) has long been implicated in impulsivity, but the precise mechanisms linking human variability in DA signaling to differences in impulsive traits remain largely unknown. By using a dual-scan positron emission tomography approach in healthy human volunteers with amphetamine and the D2/D3 ligand [18F]fallypride, we found that higher levels of trait impulsivity were predicted by diminished midbrain D2/D3 autoreceptor binding and greater amphetamine-induced DA release in the striatum, which was in turn associated with stimulant craving. Path analysis confirmed that the impact of decreased midbrain D2/D3 autoreceptor availability on trait impulsivity is mediated in part through its effect on stimulated striatal DA release.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Neurobehavioral mechanisms of impulsivity: fronto-striatal systems and functional neurochemistry.

            Impulsive acts and decisions are a part of everyday normal behavior. However, in its pathological forms, impulsivity can be a debilitating disorder often associated with a number of neuropsychiatric disorders, including attention-deficit hyperactivity disorder (ADHD). This article reviews recent progress in our understanding of the neurobiology of impulsivity using examples from recent investigations in experimental animals. Evidence is reviewed from several well-established paradigms with putative utility in assessing distinct forms of impulsive behavior in rodents, including the 5-choice serial reaction time (5CSRT) task and the delay discounting paradigm. We discuss, in particular, recent psychopharmacological and in-vivo neurochemical data in task-performing rats showing functional heterogeneity of the forebrain dopamine (DA), noradrenaline (NA), serotonin (5-HT) and acetylcholine (ACh) systems and identify how these systems normally function to facilitate flexible goal-directed behavior in situations that tax basic attentional functions and inhibitory response control mechanisms. We also discuss future research needs in terms of understanding the functional diversity of different sub-regions of prefrontal cortex (PFC) and how these systems normally interact with the striatum and main nuclei of origin of DA and NA neurons. Finally, we argue in line with others that animal paradigms are unlikely to model all aspects of complex psychiatric conditions such as ADHD but components of such syndromes may be amenable to investigation using sophisticated animal models based on highly-defined psychiatric endophenotypes.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Cortical inputs and GABA interneurons imbalance projection neurons in the striatum of parkinsonian rats.

              The striatum receives massive cortical excitatory inputs and is densely innervated by dopamine. Striatal projection neurons form either the direct or indirect pathways. Models of Parkinson's disease propose that dopaminergic degeneration imbalances both pathways, although direct electrophysiological evidence is lacking. Here, striatal neurons were identified by electrophysiological criteria and Neurobiotin labeling combined with either immunohistochemistry or in situ hybridization. Their spontaneous discharge activity and spike response to cortical stimulation were recorded in vivo in anesthetized rats rendered hemi-parkinsonian by 6-hydroxydopamine. We showed that striatonigral neurons (direct pathway) were inhibited whereas striatopallidal neurons (indirect pathway) were activated by dopaminergic lesion. We also identified, with antidromic stimulations, corticostriatal neurons that preferentially innervate striatonigral or striatopallidal neurons and showed that dopaminergic depletion selectively decreased the spontaneous activity of the former. Therefore, dopamine degeneration induces a cascade of imbalances that spread out of the basal ganglia and affect the whole basal ganglia-thalamo-cortical circuits. Fast-spiking GABA interneurons provide potent feedforward inhibition of striatal projection neurons. We showed here that these interneurons narrowed the time window of the responses of projection neurons to cortical stimulation. In the dopamine-depleted striatum, because the intrinsic activity of these interneurons was not altered, their feedforward inhibition worsened the striatal imbalance. Indeed, the time window of the evoked responses was narrower for striatonigral neurons and wider for striatopallidal neurons. Therefore, after dopaminergic depletion, cortical inputs and GABA interneurons might imbalance striatal projection neurons and represent two novel nondopaminergic mechanisms that might secondarily contribute to the pathophysiology of Parkinson's disease.
                Bookmark

                Author and article information

                Contributors
                Journal
                Neuropharmacology
                Neuropharmacology
                Neuropharmacology
                Pergamon Press
                0028-3908
                1873-7064
                1 October 2016
                October 2016
                : 109
                : 69-77
                Affiliations
                [a ]Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000, Bordeaux, France
                [b ]CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000, Bordeaux, France
                [c ]Service de neurologie de l’hôpital de Poitiers, F-86021, Poitiers, France
                [d ]Université de Poitiers, F-86000, Poitiers, France
                [e ]CIC INSERM 1402, CHU de Poitiers, Poitiers, France
                [f ]INSERM U1084 Laboratoire de Neurosciences Experimentales et Cliniques, F-86000, Poitiers, France
                [g ]Department of Pharmacology, University of Cambridge, CB2 1PD, Cambridge, UK
                [h ]Behavioural and Clinical Neuroscience Institute of the University of Cambridge, CB2 3ED, Cambridge, UK
                Author notes
                []Corresponding author. CNRS UMR 5293, Institute of Neurodegenerative Diseases, Université de Bordeaux, 146 rue Léo Saignat, 33076, Bordeaux cedex, France.CNRS UMR 5293Institute of Neurodegenerative DiseasesUniversité de Bordeaux146 rue Léo SaignatBordeaux cedex33076France pierre-olivier.fernagut@ 123456u-bordeaux.fr
                [1]

                ME and SA contributed equally.

                [2]

                DB and POF contributed equally.

                Article
                S0028-3908(16)30211-8
                10.1016/j.neuropharm.2016.05.013
                5405054
                27216859
                3ee7f1f7-eb5e-44b3-819f-5da1ca488b0d
                © 2016 The Authors

                This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

                History
                : 17 February 2016
                : 17 May 2016
                : 19 May 2016
                Categories
                Article

                Pharmacology & Pharmaceutical medicine
                parkinson,impulsivity,alpha-synuclein,pramipexole,substantia nigra

                Comments

                Comment on this article